Advertisement

Related Videos

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Aug
04
Today In Oncology
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo